TABLE 3.

PSMA Expression at First PET/CT by Systemic Treatment (n = 160)

Variable	No. of patients (n)	Proportion of patients expressing PSMA^* (n)	Median SUV_max in lesion with highest value	P
Received systemic treatment before first PET/CT^†				0.009
No	81 (50.6%)	74 (91.4%)	16.7 (IQR, 8.0–34.0)
Yes	79 (49.4%)	78 (98.7%)	29.0 (IQR, 15.0–37.7)
No. of prior therapy lines if received systemic treatment before first PET/CT				0.087
1	38 (23.8%)	37 (97.4%)	19.9 (IQR, 12.9–37.0)
2	22 (13.8%)	22 (100%)	32.4 (IQR, 20.4–37.0)
3	13 (8.1%)	13 (100%)	29.0 (IQR, 20.0–39.0)
4	6 (3.8%)	6 (100%)	25.9 (IQR, 9.8–38.0)
Last systemic treatment before first PET/CT				0.698
Abiraterone or enzalutamide	28 (17.5%)	28 (100%)	24.2 (IQR, 13.9–39.0)
Docetaxel or cabazitaxel	24 (15.0%)	23 (95.8%)	27.5 (IQR, 15.3–37.4)
Palliative, [²²³Ra]Ra-NaCl or PSMA-RLT	27 (16.9%)	27 (100%)	30.0 (IQR, 17.0–39.0)
Ongoing systemic treatment at time of first PET/CT				0.931
No	141 (88.1%)	133 (94.3%)	20.4 (IQR, 12.0–37.0)
Yes	19 (11.9%)	19 (100%)	19.7 (IQR, 9.9–35.0)
Second PET/CT				0.277
No	90 (56.3%)	86 (95.6%)	26 (IQR, 14–37)
Yes	70 (43.8%)	66 (94.3%)	18 (IQR, 9.2–37.7)

↵* SUV_max > 2.1.
↵† ADT was not considered.
IQR = interquartile range; PET/CT = positron emission tomography/computed tomography; PSMA = prostate-specific membrane antigen; PSMA-RLT = α-/β-emitter prostate-specific membrane antigen-radioligand therapy; SUV_max = maximized standardized uptake value.